A ‘bridge to a vaccine’: The race to roll out antibody-based Covid-19 drugs

Like plasma transfusions, these drugs are built on antibodies. But they’re delivered in a concentration that aims to be more effective, consistent, and able to be mass-produced. Such drugs are commonplace in treating cancer, rheumatoid arthritis, infectious diseases like Ebola, and other conditions, and represent a $50 billion annual market in the US that includes six of the country’s top 15 selling drugs.  Several companies are preparing to start clinical trials with an antibody-based Covid-19 drug, and several project they could be available by the fall.  Quartz